Tetra Radar · FDA Approvals · Decision date

Bysanti: FDA decision date

Vanda Pharmaceuticals Inc (VNDA) · 21 February 2026

Bysanti TM New Drug Application (NDA) for bipolar I disorder and schizophrenia is under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2026.

Source: 10-K of 12 February 2026

The FDA approved it on 20 February 2026.

The FDA approved BYSANTI to treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder.

Vanda Pharmaceuticals Inc on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.